Table 1. Patients and treatment characteristics.
| Characteristic | No. [%] or median (range) |
|---|---|
| Sex | |
| Male | 25 [44] |
| Female | 32 [56] |
| Median age (years) | 62 (range 38–84) |
| Stage | |
| I | 7 [12] |
| II | 20 [35] |
| III | 30 [53] |
| Site | |
| Head | 45 [78] |
| Body | 6 [11] |
| Periampullary-tail | 6 [1] |
| Median pre-treatment CA 19.9 (U/mL) | 1,155 (range <1–11,634) |
| Median radiotherapy dose (Gy) | 50.4 (range 12–64) |
| Radiotherapy modality | |
| IMRT | 56 [98] |
| 3D CRT | 1 [2] |
| Induction chemotherapy | |
| Folfirinox | 3 [5] |
| Gemcitabine | 8 [14] |
| Gemcitabine + Abraxane | 1 [2] |
| Concurrent chemotherapy | |
| Gemcitabine | 27 [47] |
| Capecitabine or 5-FU | 29 [51] |
| Bevacizumab + Capecitabine | 1 [2] |